Effect of silymarin pretreatment on the bioavailability of domperidone in healthy human volunteers

The aim of this study was to investigate the effect of silymarin pretreatment on domperidone oral bioavailability in humans. The rats were pretreated with silymarin for 7 days. The transport of domperidone across the rat intestine (duodenum, jejunum, ileum, and colon) was studied by using everted an...

Full description

Saved in:
Bibliographic Details
Published inDrug metabolism and drug interactions Vol. 29; no. 4; pp. 261 - 267
Main Authors Yamsani, Shravan Kumar, Yamsani, Madhusudan Rao
Format Journal Article
LanguageEnglish
Published Berlin De Gruyter 01.12.2014
Walter de Gruyter GmbH
Subjects
Online AccessGet full text
ISSN0792-5077
2191-0162
DOI10.1515/dmdi-2014-0013

Cover

More Information
Summary:The aim of this study was to investigate the effect of silymarin pretreatment on domperidone oral bioavailability in humans. The rats were pretreated with silymarin for 7 days. The transport of domperidone across the rat intestine (duodenum, jejunum, ileum, and colon) was studied by using everted and non-everted sac methods. Samples were collected at preset time points and replaced with buffer. The drug content in the samples was estimated. The first part of the study included oral administration of 10 mg domperidone tablet alone, and blood was sampled from the antecubital vein. The second part of the study was conducted after a washout period of 2 weeks. Five hundred milligrams of silymarin was administered twice daily for 6 days. On day 7, one tablet each of 10 mg domperidone and 500 mg silymarin were administered concomitantly. In the everted sac and non-everted sac study with silymarin pretreatment, domperidone transport increased from the duodenum, jejunum, ileum, and colon. The silymarin pretreatment increased the bioavailability of domperidone. There was a statistically significant difference in the pharmacokinetic parameters C , , AUC , and AUC The significant difference in absorption of domperidone on pretreatment with silymarin is due to the inhibition of P-glycoprotein and CYP3A. Silymarin, which inhibits CYP3A4, should be contraindicated for domperidone.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ISSN:0792-5077
2191-0162
DOI:10.1515/dmdi-2014-0013